Alpha2-adrenoceptor agonists, such as medetomidine, are frequently employed with dissociatives in veterinary anesthesia. However, these agents can elicit cardiovascular adverse effects, including vasoconstriction and bradycardia, potentially compromising tissue perfusion. Recently, Zenalpha®, a novel formulation comprising medetomidine and vatinoxan in a fixed ratio (1:20), has been introduced. This study aimed to evaluate vatinoxan’s effects in Zenalpha® on guinea pigs undergoing orchiectomy with a ketamine- medetomidine protocol. Twenty-four guinea pigs were divided into two groups. Baseline heart rate (HR), respiratory rate (RR), and rectal temperature (T°) were recorded (T0). Anesthesia was induced with intramuscular ketamine (40 mg/kg) and either medetomidine (0.4 mg/kg, Group KM) or medetomidine-vatinoxan (Zenalpha®: 0.4 mg/kg—8 mg/kg, Group KZ). Time to loss of righting reflex (LRR) was noted, and vital signs (HR, RR, peripheral oxygen saturation [SpO2], and T°) were monitored every 5 min. Orchiectomy via a scrotal approach followed, with surgical duration recorded. Subsequently, atipamezole (2 mg/kg) was administered intramuscularly, and head lift time (HL) and time to resumption of righting reflex (RRR) were recorded. No significant between-group differences were noted. The absence of significant between-group differences implies that Zenalpha® did not significantly affect cardiovascular parameters in this guinea pig cohort, despite a more marked HR reduction in the KM group versus baseline. Both groups maintained stable anesthetic parameters with no complications.
Abstracts of the ICARE 2024 78th SIAARTI National Congress
M. Serpieri;G. Bonaffini;C. Ottino;G. Quaranta;M. Mauthe von Degerfeld
2024-01-01
Abstract
Alpha2-adrenoceptor agonists, such as medetomidine, are frequently employed with dissociatives in veterinary anesthesia. However, these agents can elicit cardiovascular adverse effects, including vasoconstriction and bradycardia, potentially compromising tissue perfusion. Recently, Zenalpha®, a novel formulation comprising medetomidine and vatinoxan in a fixed ratio (1:20), has been introduced. This study aimed to evaluate vatinoxan’s effects in Zenalpha® on guinea pigs undergoing orchiectomy with a ketamine- medetomidine protocol. Twenty-four guinea pigs were divided into two groups. Baseline heart rate (HR), respiratory rate (RR), and rectal temperature (T°) were recorded (T0). Anesthesia was induced with intramuscular ketamine (40 mg/kg) and either medetomidine (0.4 mg/kg, Group KM) or medetomidine-vatinoxan (Zenalpha®: 0.4 mg/kg—8 mg/kg, Group KZ). Time to loss of righting reflex (LRR) was noted, and vital signs (HR, RR, peripheral oxygen saturation [SpO2], and T°) were monitored every 5 min. Orchiectomy via a scrotal approach followed, with surgical duration recorded. Subsequently, atipamezole (2 mg/kg) was administered intramuscularly, and head lift time (HL) and time to resumption of righting reflex (RRR) were recorded. No significant between-group differences were noted. The absence of significant between-group differences implies that Zenalpha® did not significantly affect cardiovascular parameters in this guinea pig cohort, despite a more marked HR reduction in the KM group versus baseline. Both groups maintained stable anesthetic parameters with no complications.File | Dimensione | Formato | |
---|---|---|---|
2024 JAACC- atti ICARE 2024 pag 66-67 selezione.pdf
Accesso aperto
Dimensione
1.6 MB
Formato
Adobe PDF
|
1.6 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.